OHSAWA RYUJI
No ORCID on file
· 36 papers in corpus
· active 2010-2011
Frequent coauthors
- NAKAMURA YUSUKE 36
- KONUMA AKIKO 18
- TSUNODA TAKUYA 18
- WATANABE TOMOHISA 18
- YOSHIMURA SACHIKO 18
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…